



Docket No.: V9661.0077

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Joseph Peiris et al.

Application No.: 10/807,807

Confirmation No.: 4398

Art Unit: 1648

Examiner: M. Mosher

Filed: March 24, 2004

New York, NY
September 8, 2006

For: A HIGH-THROUGHPUT DIAGNOSTIC
ASSAY FOR THE HUMAN VIRUS
CAUSING SEVERE ACUTE RESPIRATORY
SYNDROME (SARS)

RESPONSE TO RESTRICTION REQUIREMENT

U.S. Patent and Trademark Office
220 20th Street S.
Customer Window, Mail Stop Amendment
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed August 11, 2006, in which the Examiner has required restriction among the following Groups:

Group I (claims 1 and 3-6): Directed to nucleotide SEQ ID NO:2471;

Group II (claims 2-6): Directed to nucleotide SEQ ID NO:2473;

Group III (claim 7): Directed to encoded polypeptide;

Group IV (claims 8, 10, 11, 18, 19 and 29): Directed to anti-N antibody and process of use;

Application No.: 10/807,807

Docket No.: V9661.0077

Group V (claims 9-11, 18, 19 and 29): Directed to anti-S antibody and process of use;


Group VI (claims 12-14, 20-22, 25 and 26): Directed to method of detecting N gene and products used; and

Group VII (claims 15-17, 23, 24, 27 and 28): Directed to method of detecting S gene and products used,

Applicants hereby elect Group VI (claims 12-14, 20-22, 25, and 26), without traverse, for the present examination.

Dated: September 8, 2006

Respectfully submitted,

By 
Edward A. Meilman
Registration No.: 24,735
DICKSTEIN SHAPIRO LLP
1177 Avenue of the Americas
New York, New York 10036-2714
(212) 277-6500
Attorney for Applicants

IY/EAM/mgs